{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T12:29:01Z","timestamp":1780144141926,"version":"3.54.0"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Patients with pretreated relapsed\/refractory multiple myeloma (RRMM) have a poor prognosis and limited treatment options, underscoring the need for safe treatments with durable efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This Phase 2 study evaluated magrolimab (Magro) plus daratumumab (Dara) or pomalidomide\/dexamethasone (Pd) or carfilzomib\/dexamethasone (Kd) in RRMM. The primary efficacy endpoint was objective response rate (ORR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>ORR was 14.3% (Magro+Dara; <jats:italic>n<\/jats:italic> = 14), 20.0% (Magro+Pd; <jats:italic>n<\/jats:italic> = 10) and 36.4% (Magro+Kd; <jats:italic>n<\/jats:italic> = 11). There were two dose\u2010limiting toxicities: febrile neutropenia (Magro+Dara) and infusion\u2010related reaction (Magro+Pd). Grade \u2265 3 Magro\u2010related adverse event (AE) rates were 64.3% (Magro+Dara), 60.0% (Magro+Pd) and 63.6% (Magro+Kd). Two deaths were AE\u2010related; neither was Magro related.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>As the study closed early, insights into the clinical profile of Magro combinations in RRMM are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>This trial was registered at www.clinicaltrials.gov as #NCT04892446<\/jats:p><\/jats:sec>","DOI":"10.1002\/jha2.70072","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T17:58:57Z","timestamp":1749232737000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Final Results of a Phase 2 Multi\u2010Arm Study of Magrolimab Combinations in Patients With Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1002","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-8225","authenticated-orcid":false,"given":"Barry","family":"Paul","sequence":"first","affiliation":[{"name":"Atrium Health Levine Cancer Institute Wake Forest University School of Medicine  Charlotte North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Minarik","sequence":"additional","affiliation":[{"name":"Fakultni Nemocnice Olomouc  Olomouc Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7840","authenticated-orcid":false,"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[{"name":"The Ohio State University  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gasparetto","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"Cleveland Clinic  Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitul","family":"Gandhi","sequence":"additional","affiliation":[{"name":"US Oncology Site, Virginia Cancer Specialists  Fairfax Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Hillengass","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Levy","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Cancer Center  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir","family":"Manda","sequence":"additional","affiliation":[{"name":"Arizona Oncology Associates  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute  Edmonton Alberta Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah  Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"Charles University Hospital Kralovske Vinohrady  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[{"name":"Memorial Sloan\u2010Kettering Cancer Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Dong","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Leung","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Doshi","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc  Foster City California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9528-3669","authenticated-orcid":false,"given":"Christine","family":"Chen","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[{"name":"University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16172931"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01531-2"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02604"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0975"},{"key":"e_1_2_11_12_1","unstructured":"Gilead Statement on Discontinuation of Phase 3 ENHANCE\u20103 Study in AML[Press Release].2024 accessed 28 May 2025 https:\/\/www.gilead.com\/company\/company\u2010statements\/2024\/gilead\u2010statement\u2010on\u2010discontinuation\u2010of\u2010phase\u20103\u2010enhance\u20103\u2010study\u2010in\u2010aml."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02404-6"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111432"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T13:23:18Z","timestamp":1750684998000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1002\/jha2.70072"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70072","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70072"}}